Blood Reviews
Volume 23, Issue 3 , Pages 113-122 , May 2009

Bloodstream infections in haematology: Risks and new challenges for prevention

References 

  1. Cherif H, Kronvall G, Bjorkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J. 2003;4:420–426
  2. Del Giudice I, Foa R. New therapies in onco-hematology and new infectious risk factors. Rev Clin Exp Hematol. 2005;9:E1
  3. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006;132:3–12
  4. Yuen KY, Woo PC, Hui CH, et al. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant. 1998;21:1137–1143
  5. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;43(Suppl. 2):S95–S99
  6. Klastersky J. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Cancer Treat Rev. 2003;29:431–440
  7. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new?. Curr Opin Infect Dis. 2002;15:377–382
  8. Bodey GP, Rolston KV. Management of fever in neutropenic patients. J Infect Chemother. 2001;7:1–9
  9. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J. 2004;34:192–200
  10. Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther. 1999;41:145–151
  11. Potter M. New anti-cancer therapies, new opportunities for infection. Curr Opin Infect Dis. 1999;12:359–363
  12. O’Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology (Am Soc Hematol Educ Program). 2003;438–472
  13. Blijlevens NM, Donnelly JP, de Pauw BE. Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. Clin Microbiol Infect. 2001;7(Suppl. 4):47–52
  14. Gonzalez-Barca E, Carratala J, Mykietiuk A, Fernandez-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis. 2001;20:117–119
  15. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. Jama. 1992;267:1354–1358
  16. Raad I, Narro J, Khan A, Tarrand J, Vartivarian S, Bodey GP. Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients. Eur J Clin Microbiol Infect Dis. 1992;11:675–682
  17. Skov R, Gottschau A, Skinhoj P, Frimodt-Moller N, Rosdahl VT, Espersen F. Staphylococcus aureus bacteremia: a 14-year nationwide study in hematological patients with malignant disease or agranulocytosis. Scand J Infect Dis. 1995;27:563–568
  18. Ghanem GA, Boktour M, Warneke C, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore). 2007;86:54–60
  19. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249–1272
  20. Venditti M, Falcone M, Micozzi A, et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica. 2003;88:923–930
  21. Espersen F, Frimodt-Moller N, Rosdahl VT, Jessen O, Faber V, Rosendal K. Staphylococcus aureus bacteremia in patients with hematological malignancies and/or agranulocytosis. Acta Med Scand. 1987;222:465–470
  22. Favre B, Hugonnet S, Correa L, Sax H, Rohner P, Pittet D. Nosocomial bacteremia: clinical significance of a single blood culture positive for coagulase-negative staphylococci. Infect Control Hosp Epidemiol. 2005;26:697–702
  23. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine (Baltimore). 1998;77:83–101
  24. Beekmann SE, Diekema DJ, Doern GV. Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. Infect Control Hosp Epidemiol. 2005;26:559–566
  25. Ortega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005;84:40–46
  26. Velasco E, Byington R, Martins CS, Schirmer M, Dias LC, Goncalves VM. Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect. 2004;10:542–549
  27. Ninin E, Caroff N, Espaze E, et al. Assessment of ica operon carriage and biofilm production in Staphylococcus epidermidis isolates causing bacteraemia in bone marrow transplant recipients. Clin Microbiol Infect. 2006;12:446–452
  28. Engelhard D, Elishoov H, Strauss N, et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. Transplantation. 1996;61:430–434
  29. Falcone M, Micozzi A, Pompeo ME, et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother. 2004;16:540–548
  30. Christensen GD, Bisno AL, Parisi JT, McLaughlin B, Hester MG, Luther RW. Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann Intern Med. 1982;96:1–10
  31. Ashour HM, el-Sharif A. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol. 2007;25:5763–5769
  32. Wroblewska MM, Marchel H, Luczak M. Multidrug resistance in bacterial isolates from blood cultures of haematology patients. Int J Antimicrob Agents. 2002;19:237–240
  33. Pagano L, Tacconelli E, Tumbarello M, et al. Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: a problem of increasing importance. J Antimicrob Chemother. 1997;40:738–740
  34. Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad II, Safdar A. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998–2002). Medicine (Baltimore). 2005;84:303–312
  35. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European bone marrow transplantation survey. Br J Haematol. 2002;117:444–450
  36. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95:3683–3686
  37. Engelhard D, Elishoov H, Or R, et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant. 1995;16:565–570
  38. Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345:1607–1609
  39. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201–1207
  40. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002;34:1524–1529
  41. Bostrom B, Weisdorf D. Mucositis and alpha-streptococcal sepsis in bone marrow transplant recipients. Lancet. 1984;1:1120–1121
  42. Ringden O, Heimdahl A, Lonnqvist B, Malmborg AS, Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet. 1984;1:744
  43. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2002;35:1139–1146
  44. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol. 1999;20:660–663
  45. Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol. 2007;
  46. Kobayashi K, Kami M, Ikeda M, et al. Fulminant septicemia caused by Bacillus cereus following reduced-intensity umbilical cord blood transplantation. Haematologica. 2005;90:ECR06
  47. Kotiranta A, Lounatmaa K, Haapasalo M. Epidemiology and pathogenesis of Bacillus cereus infections. Microbes Infect. 2000;2:189–198
  48. Sakai C, Iuchi T, Ishii A, Kumagai K, Takagi T. Bacillus cereus brain abscesses occurring in a severely neutropenic patient: successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage. Intern Med. 2001;40:654–657
  49. Ozkocaman V, Ozcelik T, Ali R, et al. Bacillus spp. among hospitalized patients with haematological malignancies: clinical features, epidemics and outcomes. J Hosp Infect. 2006;64:169–176
  50. Riebel W, Frantz N, Adelstein D, Spagnuolo PJ. Corynebacterium JK: a cause of nosocomial device-related infection. Rev Infect Dis. 1986;8:42–49
  51. Quinn JP, Arnow PM, Weil D, Rosenbluth J. Outbreak of JK diphtheroid infections associated with environmental contamination. J Clin Microbiol. 1984;19:668–671
  52. Telander B, Lerner R, Palmblad J, Ringertz O. Corynebacterium group JK in a hematological ward: infections, colonization and environmental contamination. Scand J Infect Dis. 1988;20:55–61
  53. van der Lelie H, Leverstein-Van Hall M, Mertens M, et al. Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. Scand J Infect Dis. 1995;27:581–584
  54. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med. 1992;117:466–469
  55. Hequet O, de Jaureguiberry JP, Jaubert D, Gisserot O, Muzellec Y, Brisou P. Listeriosis after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther. 1997;39:89–91
  56. Lee SA, Raad II, Adachi JA, Han XY. Catheter-related bloodstream infection caused by Mycobacterium brumae. J Clin Microbiol. 2004;42:5429–5431
  57. Washer LL, Riddell Jt, Rider J, Chenoweth CE. Mycobacterium neoaurum bloodstream infection: report of 4 cases and review of the literature. Clin Infect Dis. 2007;45:e10–e13
  58. Levendoglu-Tugal O, Munoz J, Brudnicki A, Fevzi Ozkaynak M, Sandoval C, Jayabose S. Infections due to nontuberculous mycobacteria in children with leukemia. Clin Infect Dis. 1998;27:1227–1230
  59. Raad II, Vartivarian S, Khan A, Bodey GP. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis. 1991;13:1120–1125
  60. Vianelli N, Giannini MB, Quarti C, et al. Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. Haematologica. 2006;91:983–985
  61. Aumeran C, Paillard C, Robin F, et al. Pseudomonas aeruginosa and Pseudomonas putida outbreak associated with contaminated water outlets in an oncohaematology paediatric unit. J Hosp Infect. 2007;65:47–53
  62. Siebor E, Llanes C, Lafon I, et al. Presumed pseudobacteremia outbreak resulting from contamination of proportional disinfectant dispenser. Eur J Clin Microbiol Infect Dis. 2007;26:195–198
  63. Aubron C, Poirel L, Fortineau N, Nicolas P, Collet L, Nordmann P. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist. 2005;11:254–259
  64. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51:1905–1911
  65. Ostronoff M, Ostronoff F, Sucupira A, et al. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis. 2006;10:339–340
  66. Lin YW, Adachi S, Watanabe K, Umeda K, Nakahata T. Serial granulocyte transfusions as a treatment for sepsis due to multidrug-resistant Pseudomonas aeruginosa in a neutropenic patient. J Clin Microbiol. 2003;41:4892–4893
  67. Chan YH, Chong CY, Puthucheary J, Loh TF. Ecthyma gangrenosum: a manifestation of Pseudomonas sepsis in three paediatric patients. Singapore Med J. 2006;47:1080–1083
  68. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501–509
  69. Grigis A, Goglio A, Parea M, Gnecchi F, Minetti B, Barbui T. Nosocomial outbreak of severe Pseudomonas aeruginosa infections in haematological patients. Eur J Epidemiol. 1993;9:390–395
  70. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621–1629
  71. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis. 2004;39(Suppl. 1):S44–S48
  72. Micol JB, de Botton S, Guieze R, et al. An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica. 2006;91:1134–1138
  73. Spanik S, Krupova I, Trupl J, et al. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother. 1999;5:180–184
  74. Krcmery V, Trup J, Kunova A, et al. Imipenen-resistant P. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. Int J Clin Pharmacol Res. 1996;16:43–49
  75. Penzak SR, Gubbins PO, Stratton SL, Anaissie EJ. Investigation of an outbreak of gram-negative bacteremia among hematology–oncology outpatients. Infect Control Hosp Epidemiol. 2000;21:597–599
  76. Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist. 2005;11:68–74
  77. Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer. 2007;109:2615–2622
  78. Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol. 2003;24:269–274
  79. Labarca JA, Leber AL, Kern VL, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30:195–197
  80. Lai CH, Wong WW, Chin C, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect. 2006;12:986–991
  81. Funada H, Matsuda T. Aeromonas bacteremia in patients with hematologic diseases. Intern Med. 1997;36:171–174
  82. Taneja N, Khurana S, Trehan A, Marwaha RK, Sharma M. An outbreak of hospital acquired diarrhea due to Aeromonas sobria. Indian Pediatr. 2004;41:912–916
  83. Wolff RL, Wiseman SL, Kitchens CS. Aeromonas hydrophila bacteremia in ambulatory immunocompromised hosts. Am J Med. 1980;68:238–242
  84. Harris RL, Fainstein V, Elting L, Hopfer RL, Bodey GP. Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis. 1985;7:314–320
  85. Tsai MS, Kuo CY, Wang MC, Wu HC, Chien CC, Liu JW. Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies. J Microbiol Immunol Infect. 2006;39:150–154
  86. Martino R, Santamaria A, Pericas R, Sureda A, Brunet S. Acute rhabdomyolysis and myonecrosis complicating aeromonas bacteremia in neutropenic patients with hematologic malignancies: report of two cases. Haematologica. 1997;82:692–694
  87. Chen YH, Chen TP, Lu PL, et al. Salmonella choleraesuis bacteremia in southern Taiwan. Kaohsiung J Med Sci. 1999;15:202–208
  88. Delaloye J, Merlani G, Petignat C, et al. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?. Eur J Clin Microbiol Infect Dis. 2004;23:751–758
  89. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis. 2001;33:338–343
  90. Coleman N, Speirs G, Khan J, Broadbent V, Wight DG, Warren RE. Neutropenic enterocolitis associated with Clostridium tertium. J Clin Pathol. 1993;46:180–183
  91. Gosbell IB, Johnson CG, Newton PJ, Jelfs J. Clostridium tertium bacteremia: 2 cases and review. Pathology. 1996;28:70–73
  92. Spanik S, Trupl J, Kunova A, et al. Bloodstream infections due to anaerobic bacteria in cancer patients: epidemiology, etiology, risk factors, clinical presentation and outcome of anaerobic bacteremia. Neoplasma. 1996;43:235–238
  93. Candoni A, Fili C, Trevisan R, Silvestri F, Fanin R. Fusobacterium nucleatum: a rare cause of bacteremia in neutropenic patients with leukemia and lymphoma. Clin Microbiol Infect. 2003;9:1112–1115
  94. Slavin MA, Grigg AP, Schwarer AP. Fatal anerobic bacteremia after hematopoietic stem cell transplant. Leuk Lymphoma. 2004;45:143–145
  95. Bodey GP, Rodriguez S, Fainstein V, Elting LS. Clostridial bacteremia in cancer patients. A 12-year experience. Cancer. 1991;67:1928–1942
  96. Pirrotta MT, Bucalossi A, Forconi F, et al. Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia. Leuk Lymphoma. 2005;46:793
  97. Moses AE, Hardan I, Simhon A, et al. Clostridium septicum bacteremia and diffuse spreading cellulitis of the head and neck in a leukemic patient. Rev Infect Dis. 1991;13:525–527
  98. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991;164:731–740
  99. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–316
  100. Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol. 1999;63:77–85
  101. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32:1713–1717
  102. Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother. 2001;45:2129–2133
  103. Slavin MA. The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother. 2002;49(Suppl. 1):3–6
  104. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071–1079
  105. Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore). 1997;76:256–265
  106. Carreter de Granda ME, Richard C, Conde E, et al. Endocarditis caused by Scedosporium prolificans after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2001;20:215–217
  107. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90:999–1008
  108. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–113
  109. Alvarez M, Lopez Ponga B, Rayon C, et al. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol. 1995;33:3290–3295
  110. Tapia M, Richard C, Baro J, et al. Scedosporium inflatum infection in immunocompromised haematological patients. Br J Haematol. 1994;87:212–214
  111. Simarro E, Marin F, Morales A, Sanz E, Perez J, Ruiz J. Fungemia due to Scedosporium prolificans: a description of two cases with fatal outcome. Clin Microbiol Infect. 2001;7:645–647
  112. Barbaric D, Shaw PJ. Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol. 2001;37:122–125
  113. Jensen TG, Gahrn-Hansen B, Arendrup M, Bruun B. Fusarium fungaemia in immunocompromised patients. Clin Microbiol Infect. 2004;10:499–501
  114. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl. 1):67–75
  115. Musa MO, Al Eisa A, Halim M, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol. 2000;108:544–548
  116. Blazar BR, Hurd DD, Snover DC, Alexander JW, McGlave PB. Invasive Fusarium infections in bone marrow transplant recipients. Am J Med. 1984;77:645–651
  117. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–259
  118. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;
  119. Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–233
  120. Safdar A, Malathum K, Rodriguez SJ, Husni R, Rolston KV. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer. 2004;100:1531–1536
  121. Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12:217–223
  122. Krcmery V, Spanik S, Mrazova M, et al. Bacteremias caused by Escherichia coli in cancer patients – analysis of 65 episodes. Int J Infect Dis. 2002;6:69–73
  123. Spanik S, Trupl J, Kunova A, et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microbiol. 1997;46:517–523
  124. Raad I, Hachem R, Hanna H, et al. Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters. Eur J Clin Microbiol Infect Dis. 2007;26:549–556
  125. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18:539–544
  126. Guven GS, Uzun O, Cakir B, Akova M, Unal S. Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997–2001). Support Care Cancer. 2006;14:52–55
  127. Celebi H, Akan H, Akcaglayan E, Ustun C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant. 2000;26:211–214
  128. Clemons MJ, Valle JW, Harris M, Ellenbogen S, Howell A. Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Clin Oncol (R Coll Radiol). 1997;9:172–175
  129. Davila ML. Neutropenic enterocolitis: current issues in diagnosis and management. Curr Infect Dis Rep. 2007;9:116–120
  130. Boddie AW, Bines SD. Management of acute rectal problems in leukemic patients. J Surg Oncol. 1986;33:53–56
  131. Barnes SG, Sattler FR, Ballard JO. Perirectal infections in acute leukemia. Improved survival after incision and debridement. Ann Intern Med. 1984;100:515–518
  132. Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis. 2006;56:75–82
  133. Safdar A, Rodriguez GH, Balakrishnan M, Tarrand JJ, Rolston KV. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis. 2006;25:522–526
  134. Funada H, Machi T, Matsuda T. Changing patterns of blood culture isolates from patients with acute leukemia: a review of twenty years’ experience. Kansenshogaku Zasshi. 1992;66:1022–1029
  135. Funada H, Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. Intern Med. 1998;37:1014–1018
  136. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother. 1998;41(Suppl. D):7–11
  137. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–494
  138. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis. 1992;14(Suppl. 1):S120–S125
  139. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004;39(Suppl. 1):S25–S31
  140. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987
  141. Jugo J, Kennedy R, Crowe MJ, et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect. 2002;50:48–55
  142. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore). 2007;86:69–77
  143. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659–713; 715; 717–627; quiz 729–633.
  144. Antin JH, Guinan EC, Avigan D, et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:213–222
  145. William BM, Thawani N, Sae-Tia S, Corazza GR. Hyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management. Hematology. 2007;12:89–98
  146. van der Velden AM, Claessen AM, van Velzen-Blad H, et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine. 2007;25:8512–8517
  147. Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun. 2000;68:1435–1440
  148. Mutnick AH, Kirby JT, Jones RN. CANCER resistance surveillance program: initial results from hematology–oncology centers in North America. Chemotherapy alliance for neutropenics and the control of emerging resistance. Ann Pharmacother. 2003;37:47–56
  149. Worth LJ, Slavin MA, Brown GV, Black J. Catheter-related bloodstream infections in hematology: time for standardized surveillance?. Cancer. 2007;109:1215–1226
  150. Morrissey CO, Bardy PG, Slavin MA, et al. Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Intern Med J. 2008;38:477–495
  151. Rolston KV. Management of infections in the neutropenic patient. Annu Rev Med. 2004;55:519–526
  152. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111–118
  153. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40:1087–1093
  154. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–1552
  155. Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian fluconazole study. J Antimicrob Chemother. 2000;46:1001–1008
  156. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect. 2007;54:521–529
  157. Vos MC, Endtz HP, Horst-Kreft D, et al. Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol. 2006;44:1111–1114
  158. Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63(Suppl. 1):S1–S44
  159. Sample ML, Gravel D, Oxley C, Toye B, Garber G, Ramotar K. An outbreak of vancomycin-resistant enterococci in a hematology–oncology unit: control by patient cohorting and terminal cleaning of the environment. Infect Control Hosp Epidemiol. 2002;23:468–470
  160. Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant. 2007;39:623–629
  161. Gillespie TA, Johnson PR, Notman AW, Coia JE, Hanson MF. Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit. Clin Microbiol Infect. 2000;6:125–130
  162. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother. 1999;43:261–266
  163. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl. 4):S246–S252
  164. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007;44:15–23
  165. Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13:615–621
  166. Avery R, Kalaycio M, Pohlman B, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 2005;35:497–499
  167. Ziglam HM, Gelly KJ, Olver WJ. A survey of the antibiotic treatment of febrile neutropenia in haematology units in the United Kingdom. Clin Lab Haematol. 2005;27:374–378
  168. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607
  169. Chow AW, Jewesson PJ, Kureishi A, Phillips GL. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol. 1993;54(Suppl.):18–24
  170. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22:3163–3171
  171. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol. 2003;25:616–621
  172. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis. 2006;43:474–484
  173. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?. Ann Hematol. 2003;82:98–103
  174. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43:468–473
  175. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–659
  176. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205
  177. Obayashi T, Yoshida M, Mori T, et al. Plasma (1→3)-beta-d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995;345:17–20
  178. Cordonnier C, Herbrecht R, Buzyn A, et al. Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica. 2005;90:1102–1109
  179. Ramzi J, Mohamed Z, Yosr B, et al. Predictive factors of septic shock and mortality in neutropenic patients. Hematology. 2007;1
  180. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051

PII: S0268-960X(08)00079-9

doi: 10.1016/j.blre.2008.10.003

Blood Reviews
Volume 23, Issue 3 , Pages 113-122 , May 2009

Article Tools